Systemic treatment of recurrent meningioma
- Patrick Y Wen, MD
Patrick Y Wen, MD
- Section Editor — Neurooncology
- Professor of Neurology
- Harvard Medical School
Meningiomas account for approximately one-third of primary central nervous system tumors (table 1 and figure 1). Surgery and/or radiation therapy (RT) constitutes the initial therapeutic approach. Furthermore, surgery and/or RT are able to control disease in some patients with recurrence.
Despite the appropriate use of surgery and RT for initial management and management of recurrent disease, there is a subset of patients in whom disease cannot be controlled with these approaches. Experience with systemic therapy is limited, and most data are from observational studies. Although a number of agents have been studied, none have an established role in prolonging progression-free or overall survival .
The available data for systemic therapy is reviewed here. Topics dealing with other aspects of meningioma management include:To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009; 9:231.
- Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol 2010; 99:365.
- Koide SS. Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med 1998; 43:551.
- Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74:861.
- Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006; 24:727.
- Grunberg SM, Rankin C, Townsend J. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clinical Oncol 2001; 20:56a.
- Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993; 15:75.
- Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas--a pilot study. Surg Neurol 1985; 24:245.
- Swinnen LJ, Rankin C, Rushing EJ. Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma. J Clin Oncol 2009; 27:15s.
- Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004; 62:1210.
- Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996; 84:733.
- Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 1991; 27:416.
- Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997; 40:271.
- Muhr C, Gudjonsson O, Lilja A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 2001; 7:2269.
- Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 2008; 113:2146.
- García-Luna PP, Relimpio F, Pumar A, et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci 1993; 37:237.
- Rünzi MW, Jaspers C, Windeck R, et al. Treatment of meningioma with octreotide. Lancet 1989; 2:217.
- Jaffrain-Rea ML, Minniti G, Santoro A, et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg 1998; 100:40.
- Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007; 69:969.
- Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 2014; 73:919.
- Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015; 84:280.
- Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009; 11:853.
- Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 2012; 106:409.
- Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010; 96:211.
- Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012; 109:63.
- Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012; 109:187.
- Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 2015; 17:116.
- Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol 2014; 117:93.
- Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45:285.
- Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339:1077.
- Du Z, Abedalthagafi M, Aizer AA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 2015; 6:4704.